Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 169

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence

Open access
Janni, Wolfgang, Rack, Brigitte, Schindlbeck, Christian, Strobl, Barbara, Rjosk, Dorothea, Braun, Stephan, Sommer, Harald, Pantel, Klaus, Gerber, Bernd, Friese, Klaus · 2005 · Cancer

Abstract

BACKGROUND: The prognostic significance of isolated tumor cells (ITCs) in bone marrow (BM) from patients with breast carcinoma at the time of their primary diagnosis recently was been confirmed by a large pooled analysis. If the persistence of ITCs after adjuvant therapy confers a similar risk for recurrence, then it would be an indication to consider secondary adjuvant therapy. METHODS: The authors analyzed BM aspirates from 228 patients during recurrence‐free follow‐up at a median interval ± standard deviation (SD) of 21.3 ± 29.1 months after a primary diagnosis of breast carcinoma (pathologic T1 [pT1]–pT2, pN0–pN3, pM0). Carcinoma cells were detected using a standardized immunoassay with monoclonal antibody A45‐B/B3 directed against cytokeratin (CK). Patients were followed for a median ± SD of 49.8 ± 32.1 months after their primary diagnosis. RESULTS: Persistent ITCs in BM were detected in 12.7% of patients (n = 29 patients). Positive BM status was more frequent (15.7%) within the first 21 months after primary diagnosis than after a follow‐up > 21 months (9.7%). The Kaplan–Meier estimate for mean recurrence‐free survival was 149.7 months (95% confidence interval [95% CI], 139.6–159.8 months) in patients with negative BM status and 86.5 months (95% CI, 65.7–107.4 months; P = 0.0003) in patients with positive BM status at the time patients underwent follow‐up BM aspiration. Patients who were without evidence of persistent ITCs had a significantly longer overall survival (162.1 months; 95% CI, 152.1–172.0 months) compared with patients who had positive BM status (overall survival, 98.7 months; 95% CI, 79.7–117.9 months; P = 0.0008). In multivariate Cox regression analysis that included BM status, tumor size, lymph node status, and histopathologic grade, evidence of ITCs was an independent significant predictor for reduced disease‐free survival (relative risk [RR], 4.57; P < 0.0001) and overall survival (RR, 5.57; P = 0.002). Persistent ITCs had the greatest prognostic relevance when they were detected between 25 months and 42 months after primary diagnosis (RR, 7.68). CONCLUSIONS: Evidence of persistent ITCs in BM from patients with breast carcinoma indicated an increased risk for subsequent recurrence. Prospective trials should investigate the benefit of secondary adjuvant treatment on the basis of BM marrow status. Cancer 2005. © 2005 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.20834

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 169

Metadata

Authors
Janni, W., Rack, B., Schindlbeck, C., Strobl, B., Rjosk, D., Braun, S., Sommer, H., Pantel, K., Gerber, B., & Friese, K.
Venue
Cancer
Publisher
Wiley
Published
2005-01-21
Volume
103
Issue
5
Pages
884-891
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1980143004
Cited by
169
References
1
FWCI
6.08
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.